Banking immune cells from recovered COVID-19 patients

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This study aims to establish a biobank for preserving and producing cellular immunotherapy using T lymphocytes from convalescent COVID-19 donors. Patients hospitalized for COVID-19 at the University Hospital of Nancy will be approached for participation after recovery, specifically those with demonstrated cellular immunity against SARS-CoV-2. Blood samples will be collected and tested for various infectious markers to ensure safety before banking the immune cells. The goal is to explore the feasibility of using these cells to improve outcomes for patients with severe COVID-19.

Why it matters

Who can join: the full rules

Inclusion Criteria:

* Patient hospitalised for proved SARS-CoV-2 infection in the infectious disease unit of the Nancy University Hospital who received a comprehensive information about the study, and accepted to participate
* Patient who has an active cellular immunity against SARS-CoV-2 (biological definition: Elispot IFNgamma : \> 50 SFC/106 PBMC)

Exclusion Criteria:

* Patient hospitalised in Intensive car unit
* Patient with haemoglobin \< 10 g/dl
* Patient who take hypertension medication
* Patient with cardiovascular history: Valvulopathy, conduction rythm disorders, arterial vascular insufficiency, congenital anomalies
* Patient with auto-immune disease
* Patient with medical history of solid or hematopoietic graft
* Patient with active malignant disease (haematological or neoplasm) or considered in remission since less than 2 years
* Patient with psychiatric disorders
* Patient subject to a legal protection measure.
* Patient with proved infectious disease
* Asplenic patient
* Pregnant or breastfeeding woman
* Woman without contraception

Where it's running

• CHRU-Nancy - Hopitaux de Brabois - Batiment Philippe Canton
  Vandœuvre-lès-Nancy, Lorraine, France Recruiting

Study contacts

• Study coordinator: Benjamin Lefèvre
• Email: b.lefevre@chru-nancy.fr
• Phone: +33383157654

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Comparative Immunogenicity of Respiratory Virus Vaccines (CIRV2) in Adults

  This study tests and compares the immune responses and tolerability of the latest COVID-19 vaccines from Novavax and Pfizer/BioNTech in adults at risk for severe COVID-19.

  Recruiting Phase 4 Henry M. Jackson Foundation for the Advancement of Military Medicine · Bethesda, Maryland · NCT07287137

• Omicron-based COVID-19 vaccine with Matrix-M given as a single dose in older adults and high-risk individuals

  A single-dose Omicron-subvariant vaccine with Matrix-M is tested to see if it is safe and can induce an immune response in adults 65+ and in younger adults with conditions that raise the risk of severe COVID-19, who were previously vaccinated.

  Recruiting at 20 sites Phase 4 Sanofi · Fair Oaks, California and 19 other locations · NCT07861542

• Secutrelvir for nonhospitalized COVID-19 in teens and adults

  This study tests whether secutrelvir can help nonhospitalized people with COVID-19 see faster symptom relief compared with a placebo.

  Recruiting Phase 3 Shionogi Inc. · Multiple Locations · NCT07746544

• Virological Monitoring of Seasonal Respiratory Infections in France

  This project tests how often common respiratory viruses show up in patients seen by primary care doctors in metropolitan France during the fall and winter.

  Recruiting Institut National de la Santé Et de la Recherche Médicale, France · Paris · NCT07599449

• COVID-19 Registry at San Matteo (SMACORE) - patient-matching observational registry

  This registry tests how COVID-19 patients are being treated and progress across San Matteo in Pavia to understand patterns and outcomes.

  Recruiting Fondazione IRCCS Policlinico San Matteo di Pavia · Pavia · NCT07597876

• MDX2301 in healthy adults and adults at higher risk for severe COVID-19

  This study will try single and repeat doses of MDX2301 given by IV, IM, or SC to see if they are safe and trigger neutralizing activity in healthy adults and adults at higher risk for severe COVID-19.

  Recruiting at 2 sites Phase 1 ModeX Therapeutics, An OPKO Health Company · Las Vegas, Nevada and 1 other locations · NCT07445971

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.